Search Result

Results for "

adenocarcinoma

" in MCE Product Catalog:

By Targets:	Akt (1) Antibiotic (2) Apoptosis (15) Arp2/3 Complex (1) Autophagy (3) Bacterial (2) c-Met/HGFR (1) c-Myc (1) Calcium Channel (2) Caspase (3) CD3 (1) CDK (2) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (1) Drug Metabolite (2) Drug-Linker Conjugates for ADC (1) Endogenous Metabolite (3) Epigenetic Reader Domain (1) ERK (1) Estrogen Receptor/ERR (1) Eukaryotic Initiation Factor (eIF) (1) FAK (1) Farnesyl Transferase (1) Ferroptosis (1) Galectin (1) HDAC (1) HSP (1) Interleukin Related (1) MAP4K (1) MDM-2/p53 (1) MEK (2) MMP (3) mTOR (1) NAMPT (2) Orexin Receptor (OX Receptor) (2) PARP (3) PD-1/PD-L1 (1) Phosphatase (1) Phosphodiesterase (PDE) (1) Phospholipase (1) Ras (2) Reactive Oxygen Species (3) RET (1) Ribosomal S6 Kinase (RSK) (1) Sirtuin (1) SOD (1) Wnt (1)
By Research Areas:	Cancer (75) Endocrinology (3) Infection (2) Inflammation/Immunology (4) Metabolic Disease (1) Neurological Disease (4)

By Targets:

Akt (1)

Antibiotic (2)

Apoptosis (15)

Arp2/3 Complex (1)

Autophagy (3)

Bacterial (2)

c-Met/HGFR (1)

c-Myc (1)

Calcium Channel (2)

Caspase (3)

CD3 (1)

CDK (2)

DNA Alkylator/Crosslinker (1)

DNA/RNA Synthesis (1)

Drug Metabolite (2)

Drug-Linker Conjugates for ADC (1)

Endogenous Metabolite (3)

Epigenetic Reader Domain (1)

ERK (1)

Estrogen Receptor/ERR (1)

Eukaryotic Initiation Factor (eIF) (1)

FAK (1)

Farnesyl Transferase (1)

Ferroptosis (1)

Galectin (1)

HDAC (1)

HSP (1)

Interleukin Related (1)

MAP4K (1)

MDM-2/p53 (1)

MEK (2)

MMP (3)

mTOR (1)

NAMPT (2)

Orexin Receptor (OX Receptor) (2)

PARP (3)

PD-1/PD-L1 (1)

Phosphatase (1)

Phosphodiesterase (PDE) (1)

Phospholipase (1)

Ras (2)

Reactive Oxygen Species (3)

RET (1)

Ribosomal S6 Kinase (RSK) (1)

Sirtuin (1)

SOD (1)

Wnt (1)

By Research Areas:

Cancer (75)

Endocrinology (3)

Infection (2)

Inflammation/Immunology (4)

Metabolic Disease (1)

Neurological Disease (4)

Inhibitors & Agonists

Screening Libraries

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas

HY-P99350

Gresonitamab AMG 910; Anti-Human CD3xClaudin18 2	CD3	Cancer
Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma.

HY-137301

Mycophenolic acid glucuronide	Drug Metabolite	Cancer
Mycophenolic acid glucuronide is a metabolite of the immunosuppressant mycophenolic acid (MPA). Mycophenolic acid glucuronide shows anti-tumor activity and can be used in adenocarcinoma research.

HY-W451275

HG106	Others	Cancer
HG106 is a potent SLC7A11 inhibitor. HG106 markedly decreased cystine uptake and intracellular glutathione biosynthesis. HG106 can be used for the research of KRAS-mutant lung adenocarcinoma.

HY-138793

2-(2,6-Dioxopiperidin-3-yl)phthalimidine EM-12	Others	Cancer
2-(2,6-Dioxopiperidin-3-yl)phthalimidine (EM-12), a teratogenic Thalidomide analogue, is more active than Thalidomide and is much more stable for hydrolysis. 2-(2,6-Dioxopiperidin-3-yl)phthalimidine enhances 1,2-dimethylhydrazine-induction of rat colon adenocarcinomas.

HY-153590

PARP-1-IN-4	PARP	Cancer
PARP-1-IN-4 is a PARP-1 inhibitor. PARP-1-IN-4 has inhibitory activity against PARP-1 with IC₅₀ value of 302 μM. PARP-1-IN-4 can be used for the research of lung adenocarcinoma.

HY-114356

BPI-9016M	c-Met/HGFR	Cancer
BPI-9016M is a potent, orally active, and selective dual c-Met and AXL tyrosine kinases inhibitor. BPI-9016M suppresses tumor cell growth, migration and invasion of lung adenocarcinoma.

HY-118091A

Bexlosteride LY300502	Others	Cancer
Bexlosteride (LY300502) is a benzoquinolinone human type I 5α-reductase inhibitor. Bexlosteride shows metabolic inhibitory, antiproliferative, and antisecretory effects in LNCaP human prostatic adenocarcinoma cell cultures. Bexlosteride can be used for the research of prostatic cancer.

HY-106588

Heptaplatin SKI 2053R	DNA Alkylator/Crosslinker	Cancer
Heptaplatin (SKI 2053R) is a platinum derivative with anticancer activity against various cancer cell lines, including cisplatin-resistant tumor cell lines. SKI-2053R is active in the research of gastric adenocarcinoma and has favorable toxicity profiles.

HY-147838

Nampt-IN-9

NAMPT Cancer

Nampt-IN-9 (Compound 8) is a potent NAMPT inhibitor with anticancer activities. Nampt-IN-9 can be used for pancreatic ductal adenocarcinoma research.

Nampt-IN-9	NAMPT	Cancer
Nampt-IN-9 (Compound 8) is a potent NAMPT inhibitor with anticancer activities. Nampt-IN-9 can be used for pancreatic ductal adenocarcinoma research.

HY-147030

PARP1-IN-8	PARP	Cancer
PARP1-IN-8 (compound 11c) is a potent and BBB-penetrated PARP1 inhibitor, with an IC₅₀ of 97 nM. PARP1-IN-8 shows significantly potent anti-proliferative activity against Human lung adenocarcinoma epithelial cell line A549.

HY-P99351

Andecaliximab Anti-MMP9 Reference Antibody (andecaliximab)	MMP	Cancer
Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF).

HY-101194

Tin protoporphyrin IX dichloride Maximum Cited Publications 14 Publications Verification Tin-protoporphyrin IX; Sn-Protoporphyrin; SnPPIX	Reactive Oxygen Species	Cancer
Tin protoporphyrin IX dichloride (SnPPIX) is a potent Heme oxygenase-1 (HO-1) inhibitor. Tin protoporphyrin IX dichloride sensitizes pancreatic ductal adenocarcinoma (PDAC) tumors to chemotherapy in mice model.

HY-144361

Antitumor agent-44	Apoptosis	Cancer
Antitumor agent-44 (Compound 5n) disrupts the mitochondrial homeostasis, induces cell cycle arrest and apoptosis in human adenocarcinoma cells. Antitumor agent-44 (Compound 5n) possesses good anti-tumor activity in a lung-cancer-cell xenograft mice model.

HY-156027

SIRT6-IN-3	Sirtuin HDAC Akt mTOR Ribosomal S6 Kinase (RSK) ERK	Cancer Endocrinology Inflammation/Immunology Neurological Disease
SIRT6-IN-3 (compound 8a) is a selective inhibitor of SIRT6 (IC₅₀=7.49 μM). SIRT6-IN-3 inhibits pancreatic ductal adenocarcinoma (PDAC) cells proliferation and induces apoptosis. SIRT6-IN-3 increases the sensitivity of cancer cells to gemcitabine (HY-17026) via blocking the DNA damage repair pathway. SIRT6-IN-3 is used in pancreatic cancer research.

HY-147027

PARP-1-IN-2	PARP Caspase Apoptosis	Cancer
PARP-1-IN-2 (compound 11g) is a potent and BBB-penetrated PARP1 inhibitor, with an IC₅₀ of 149 nM. PARP1-IN-2 shows significantly potent anti-proliferative activity against Human lung adenocarcinoma epithelial cell line A549. PARP1-IN-2 can induce A549 cells apoptosis.

HY-P99941

Retifanlimab	PD-1/PD-L1	Cancer
Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA).

HY-147328

LCS3	Apoptosis	Cancer
LCS3 is a reversible and uncompetitive glutathione disulfide reductase (GSR) and thioredoxin reductase 1 (TXNRD1) inhibitor (IC₅₀=3.3 µM and 3.8 µM, respectively). LCS3 shows anti-tumor activity, and induces apoptosis. LCS3 can be used in lung adenocarcinoma (LUAD) research.

HY-151565

Anticancer agent 86

Others Cancer

Anticancer agent 86 (compound 6i) shows potential activity against breast adenocarcinoma.

Anticancer agent 86	Others	Cancer
Anticancer agent 86 (compound 6i) shows potential activity against breast adenocarcinoma.

HY-122723

GOT1 inhibitor-1 1 Publications Verification	Others	Cancer
GOT1 inhibitor-1 (compound 2c), a tryptamine-based derivative, acts as a novel, potent and non-covalent inhibitor of glutamate oxaloacetate transaminase 1 (GOT1) with an IC₅₀ of 8.2 uM. GOT1 inhibitor-1 can be used for the research of pancreatic ductal adenocarcinoma (PDAC).

HY-P99379

Nidanilimab CAN04; Anti-IL-1RAP/IL-1R3 Reference Antibody (nidanilimab)	Interleukin Related	Cancer
Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a K_d value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .

HY-N9480

Vinaxanthone SM-345431	Phospholipase	Cancer
Vinaxanthone (SM-345431) is a potent and selective semaphorin3A inhibitor. Vinaxanthone exhibits semaphorin3A inhibiting activity with an IC₅₀ of 0.1-0.2 μM. Vinaxanthone shows selective inhibitory activity against phospholipase C (PLC) from rat brain, mutine colon 26 Adenocarcinoma and murine fibroblasts NIH3T3 with IC₅₀s being 5.4, 9.3 and 44 μM, respectively.

HY-N10777

1-Ketoaethiopinone	Others	Cancer
1-Ketoaethiopinone is an abietane-diterpenoid. 1-Ketoaethiopinone has an α, β-unsaturated carbonyl function. 1-Ketoaethiopinone shows cytotoxic activity against human cancer cell lines MOLT-4 (human lymphoblastic leukemia) and MCF-7 (human breast adenocarcinoma).

HY-100498

GSK2256098 1 Publications Verification	FAK Apoptosis	Cancer
GSK2256098 is a selective FAK kinase inhibitor, which inhibits growth and survival of pancreatic ductal adenocarcinoma cells.

HY-139639

MEK4 inhibitor-2

MEK Cancer

MEK4 inhibitor-2 is a novel MEK4 inhibitor against pancreatic adenocarcinoma with an IC₅₀ value of 83 nM.
HY-139638

MEK4 inhibitor-1

MEK Cancer

MEK4 inhibitor-1 is a novel MEK4 inhibitor against pancreatic adenocarcinoma with an IC₅₀ value of 61 nM.
HY-W015084

β-Ionone

Apoptosis Cancer

β-Ionone is effective in the induction of apoptosis in gastric adenocarcinoma SGC7901 cells. Anti-cancer activity.

MEK4 inhibitor-2	MEK	Cancer
MEK4 inhibitor-2 is a novel MEK4 inhibitor against pancreatic adenocarcinoma with an IC₅₀ value of 83 nM.

MEK4 inhibitor-1	MEK	Cancer
MEK4 inhibitor-1 is a novel MEK4 inhibitor against pancreatic adenocarcinoma with an IC₅₀ value of 61 nM.

β-Ionone	Apoptosis	Cancer
β-Ionone is effective in the induction of apoptosis in gastric adenocarcinoma SGC7901 cells. Anti-cancer activity.

HY-148260

KRAS G12D inhibitor 16	Ras	Cancer
KRAS G12D inhibitor 16 is a KRAS G12D inhibitor. KRAS G12D inhibitor 16 has inhibitory activity against KRAS G12D and KRAS G12D mutation with IC₅₀ value of 0.7 nM and 0.35 μM, respectively. KRAS G12D inhibitor 16 can be used for the research of many malignant tumor, such as pancreatic ductal adenocarcinomas (PDAC), colon and rectal carcinomas (CRC), non-small cell lung carcinomas (NSCLC).

HY-138098

Sartorypyrone B	Others	Cancer
Sartorypyrone B is a 2β-acetoxyl analogue of chevalone C. Sartorypyrone B is yielded from the ethyl acetate extract of the culture of the marine sponge-associated fungus Neosartorya tsunodae (KUFC 9213). Sartorypyrone B exhibits strong growth inhibitory activity, having GI₅₀s of 17.8, 20.5, and 25.0 μM, respectively, for MCF-7, NCI-H460, and A375-C5. Sartorypyrone B has the potential for the research of breast adenocarcinoma, non-small cell lung cancer, and melanoma diseases.

HY-151570

Anticancer agent 87

Others Cancer

Anticancer agent 87 is a potent anticancer agent. Anticancer agent 87 can be used in the research of breast adenocarcinoma and liver cancer.
HY-151572

Anticancer agent 88

Others Cancer

Anticancer agent 88 is a potent anticancer agent. Anticancer agent 88 can be used in the research of breast adenocarcinoma and liver cancer.

Anticancer agent 87	Others	Cancer
Anticancer agent 87 is a potent anticancer agent. Anticancer agent 87 can be used in the research of breast adenocarcinoma and liver cancer.

Anticancer agent 88	Others	Cancer
Anticancer agent 88 is a potent anticancer agent. Anticancer agent 88 can be used in the research of breast adenocarcinoma and liver cancer.

HY-N5093

Glucodigifucoside	Others	Cancer
Glucodigifucoside, a cardenolide glycoside that could be isolated from the seeds of Digitalis purpurea, exhibits potent cytotoxicity against human renal adenocarcinoma cell line ACHN.

HY-N10363

Pixinol	Others	Cancer
Pixinol, a natural glycoside, shows cytotoxicity against the human lung carcinoma GLC4 and adenocarcinoma COLO 320 cell lines (IC₅₀=71 µM and 43 µM, respectively).

HY-124414

4'-Hydroxytamoxifen	Estrogen Receptor/ERR Drug Metabolite	Cancer
4'-Hydroxytamoxifen is a metabolite of Tamoxifen. 4'-Hydroxytamoxifen shows higher affinity for the ER than Tamoxifen. 4'-Hydroxytamoxifen induces a non-apoptotic cytotoxic effect in human endometrial adenocarcinoma cells.

HY-W015084S

β-Ionone-13C3	Apoptosis	Cancer
β-Ionone-¹³C₃ is the ¹³C-labeled β-Ionone. β-Ionone is effective in the induction of apoptosis in gastric adenocarcinoma SGC7901 cells. Anti-cancer activity[1].

HY-111320

Chrysomycin B	Bacterial Antibiotic	Cancer
Chrysomycin B is an antibiotic isolated from a strain of Streptomyces. Chrysomycin B causes DNA damage in the human lung adenocarcinoma A549 cell line and inhibits topoisomerase II. Chrysomycin B suppresses the growth of transplantable tumors in mice.

HY-114409

GB1107 5 Publications Verification	Galectin	Cancer
GB1107 is a potent, selective, orally active inhibitor of Galectin-3 (Gal-3) with a K_d of 37 nM for human Galectin-3. GB1107 reduces human and mouse lung adenocarcinoma growth and blocks metastasis in the syngeneic model.

HY-N6005

Methyl caffeate	Bacterial	Cancer Infection
Methyl caffeate, an antimicrobial agent, shows moderate antimicrobial and prominent antimycobacterial activities. Methyl caffeate also exhibits α-glucosidase inhibition activity, oxidative stress inhibiting activity, anti-platelet activity, antiproliferative activity in cervix adenocarcinoma and anticancer activity in lung and leukmia cell lines.

HY-N6237

Aspulvinone O	Reactive Oxygen Species	Infection
Aspulvinone O is a natural inhibitor of aspartate transaminase 1 (GOT1). GOT1 plays an important role in energy metabolism and Reactive Oxygen Species (ROS) balance. GOT1 may serve as an important target in PDAC. Aspulvinone O suppresses pancreatic ductal adenocarcinoma cells growth by interfering glutamine metabolism.

HY-115579

MALAT1-IN-1 1 Publications Verification	Others	Cancer
MALAT1-IN-1 (compounds 5) is a potent and specific Malat1 (Metastasis-associated lung adenocarcinoma transcript 1) inhibitor. MALAT1-IN-1 modulated Malat1 downstream genes in a dose-dependent manner without affecting expression of nuclear enriched abundant transcript 1 (Neat1) .

HY-113056A

N1-Acetylspermidine hydrochloride	Endogenous Metabolite	Cancer
N1-Acetylspermidine hydrochloride is an acetyl derivative of polyamine. N1-acetylspermine is the substrate for the polyamine oxidase (PAO). N1-Acetylspermidine hydrochloride selectively elevates its level in human colorectal adenocarcinomas. N1-acetylspermidine shows cleavage efficiency at apurinic sites in DNA.

HY-100429

CAN508	CDK	Cancer
CAN508 is a potent, ATP-competitive CDK9/cyclin T1 inhibitor with an IC₅₀ of 0.35 μM. CAN508 exhibits a 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. Antitumor activity.

HY-14392

5,6-Dichlorobenzimidazole riboside 1 Publications Verification DRB	CDK	Cancer
5,6-Dichlorobenzimidazole riboside is a nucleoside analog that inhibits several carboxyl-terminal domain (CTD) kinases including casein kinase II and CDKs. 5,6-Dichlorobenzimidazole riboside trigger p53-dependent apoptosis of human colon adenocarcinoma cells without inducing genotoxic stress to healthy cells.

HY-34595

Pyrazoloadenine

RET Cancer

Pyrazoloadenine is a potent RET (REarranged during Transfection) lung cancer oncoprotein inhibitor. Pyrazoloadenine shows anticancer activity.

Pyrazoloadenine	RET	Cancer
Pyrazoloadenine is a potent RET (REarranged during Transfection) lung cancer oncoprotein inhibitor. Pyrazoloadenine shows anticancer activity.

HY-147008

XP-524	Epigenetic Reader Domain	Cancer
XP-524 is a potent BET and EP300 inhibitor. XP-524 shows great tumoricidal activity in vivo. XP-524 prevents KRAS-induced, neoplastic transformation in vivo and extends survival in two transgenic mouse models of aggressive PDAC. XP-524 also enhances the presentation of self-peptide and tumor recruitment of cytotoxic T lymphocytes. XP-524 has the potential for the research of pancreatic ductal adenocarcinoma (PDAC).

HY-113056AS

N1-Acetylspermidine-d6 hydrochloride	Endogenous Metabolite	Cancer
N1-Acetylspermidine-d₆ (hydrochloride) is the deuterium labeled N1-Acetylspermidine hydrochloride. N1-Acetylspermidine hydrochloride is an acetyl derivative of polyamine. N1-acetylspermine is the substrate for the polyamine oxidase (PAO). N1-Acetylspermidine hydrochloride selectively elevates its level in human colorectal adenocarcinomas. N1-acetylspermidine shows cleavage efficiency at apurinic sites in DNA[1][2][3].

HY-124745

KY-05009	MAP4K Wnt Apoptosis	Cancer
KY-05009 is an ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with a K_i of 100 nM. KY-05009 pharmacologically inhibits TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cells. KY-05009 inhibits the protein expression of TNIK and transcriptional activity of Wnt target genes and induces apoptosis in cancer cells. KY-05009 exerts anti-cancer activity.

HY-151295

Antitumor agent-75	Others	Cancer
Antitumor agent-75 is a novel potent antitumor agent. Antitumor agent-75 has cytotoxic effects on cancer and normal human cell lines. Antitumor agent-75 shows a highly selective cytotoxic effect against human lung adenocarcinoma (cell line A549) when combined with Antitumor agent-74 (HY-151292), the IC₅₀ value of 2.8 μM. Antitumor agent-75 can be used for the research of cancer.

HY-126350

CL2-SN-38	Drug-Linker Conjugates for ADC	Cancer
CL2-SN-38 is a cleavable linker-based agent-Linker conjugate, it can conjugate with the anti-Trop-2-humanized antibody hRS7. CL2-SN-38 can be used for the reasearch of cancer.

HY-135793

Macropa-NH2 diester	Others	Cancer
Macropa-NH2 diester is a compound can be used for imaging during the investigation of cancer. Macropa-NH2 diester is compound 210 extracted from patent WO2018187631.

HY-100669

Mycro 3 4 Publications Verification	c-Myc Autophagy	Cancer
Mycro 3 is an orally active, potent and selective inhibitor of Myc-associated factor X (MAX) dimerization. Mycro 3 also inhibit DNA binding of c-Myc. Mycro 3 could be used for the research of pancreatic cancer.

HY-14769

Folitixorin 1 Publications Verification 5,10-Methylenetetrafolate; ANX-510 free acid	Endogenous Metabolite	Cancer
Folitixorin (5,10-methylenetetrahydrofolate) is a cofactor and an analog of leucovorin. Folitixorin is a promising agent for modulation of 5-FU cytotoxicity in adjuvant cancer research.

HY-135985

DCLK1-IN-1 1 Publications Verification	Others	Cancer
DCLK1-IN-1 is a selective, oral bioavailability in vivo-compatible chemical probe of the doublecortin like kinase 1 (DCLK1 kinase) domain. DCLK1-IN-1 inhibits DCLK1 and DCLK2 kinases (IC₅₀: DCLK1=9.5/57.2 nM and DCLK2=31/103 nM in binding and kinase assay, respectively). DCLK1-IN-1 shows low toxicity, and can investigate DCLK1 biology and establish its role in cancer, like DCLK1⁺ pancreatic ductal adenocarcinoma (PDAC).

HY-100513A

Dehydroaltenusin	Apoptosis DNA/RNA Synthesis Antibiotic	Cancer
Dehydroaltenusin is a small molecule selective inhibitor of eukaryotic DNA polymerase α, a type of antibiotic produced by a fungus with an IC₅₀ value of 0.68 μM. The inhibitory mode of action of dehydroaltenusin against mammalian pol α activity is competitive with respect to the DNA template primer (K_i=0.23 µM) and non-competitive with respect to the 2'-deoxyribonucleoside 5'-triphosphate substrate (K_i=0.18 µM). Dehydroaltenusin arrests the cancer cell cycle at the S-phase and triggers apoptosis. Dehydroaltenusin possesses anti-tumor activity against human adenocarcinoma tumor in vivo.

HY-148409

MMRi62	Ferroptosis Apoptosis Autophagy MDM-2/p53	Cancer
MMRi62, a ferroptosis inducer targeting MDM2-MDM4 (negative regulators of tumor suppressor p53). MMRi62 shows a P53-independent pro-apoptotic activity against pancreatic ductal adenocarcinoma (PDAC) cells and induce autophagy. MMRi62 inducesferroptosis, resulting in a increase of reactive oxygen and lysosomal degradation of ferritin heavy chain (FTH1). MMRi62 also leads to proteasomal degradation of mutant p53, also inhibits orthotopic xenograft PDAC mouse model in vivo with high frequency mutation characteristics of KRAS and TP53.12.

HY-19824

3PO Maximum Cited Publications 14 Publications Verification	Autophagy	Cancer
3PO is an inhibitor of PFKFB3. 3PO attenuates the proliferation of several cancer cell lines with IC₅₀s of 1.4-24 μmol/L. 3PO suppresses glucose uptake and decreases the intracellular concentration of Fru-2,6-BP, lactate, ATP, NAD⁺ and NADH. 3PO can be used for the research of cancer.

HY-156694

Hydroxy-PP-Me	Apoptosis	Cancer
Hydroxy-PP-Me is a potent and specific CBR1 inhibitor with an IC₅₀ of 759 nM. Hydroxy-PP-Me inhibits serum-withdrawal-induced apoptosis. Hydroxy-PP-Me increases As₂O₃-induced apoptotic cell death compared with As₂O₃ alone.

HY-N3065

Pierreione B	Others	Cancer
Pierreione B is a pyranoisoflavone, that can be isolated from the leaves and twigs of Antheroporum pierrei. Pierreione B demonstrates solid tumor selectivity with minimal cytotoxicity.

HY-122751

(R)-DNMDP	Phosphodiesterase (PDE)	Cancer
(R)-DNMDP is a potent and selective cancer cell cytotoxic agent. (R)-DNMDP, the R-form of DNMDP, binds PDE3A directly. (R)-DNMDP has a 500-fold lower EC₅₀ compared to the (S)-enantiomer in HeLa cell line.

HY-135008

J14 2 Publications Verification	Reactive Oxygen Species	Cancer
J14 is a reversible sulfiredoxin inhibitor with an IC₅₀ of 8.1 μM. J14 induces oxidative stress (intracellular ROS accumulation) by inhibiting sulfiredoxin, leading to cytotoxicity and cancer cell death.

HY-118916A

FTI-2148 diTFA	Farnesyl Transferase	Cancer
FTI-2148 diTFA is a RAS C-terminal mimetic dual farnesyl transferase (FT-1) and geranylgeranyl transferase-1 (GGT-1) inhibitor with IC₅₀s of 1.4 nM and 1.7 μM, respectively.

HY-15866

FR901465

Others Cancer

FR901465 is a potent anti-cancer and anti-tumor agent. FR901465 can be used for cancer research.

HY-19808

C-DIM12 1 Publications Verification	Apoptosis	Cancer Inflammation/Immunology Neurological Disease
C-DIM12 is a potent, orally active Nurr1 antagonist. C-DIM12 inhibits the tumor growth and autophagy, and induces the cell apoptosis. C-DIM12 has anti-inflammatory and neuroprotective effects, and can be used for cancer and neurological disease study.

HY-120272

SMAP-2

DT-1154
Phosphatase Cancer

SMAP-2 (DT-1154) is an orally active protein phosphatase 2A (PP2A) activator, with anti-cancer activity.

HY-17547

NMS-E973 2 Publications Verification	HSP	Cancer
NMS-E973 is a potent and selective inhibitor of HSP90. NMS-E973 binds to the ATP binding site of Hsp90α with a DC₅₀ of <10 nM. NMS-E973 is able to cross the blood-brain barrier (BBB). Antitumor efficacy.

HY-16931

SMIFH2

1 Publications Verification

Arp2/3 Complex Cancer

SMIFH2 is a formin specific inhibitor. SMIFH2 inhibits actin polymerization by Formins and affects the actin cytoskeleton.
HY-151287

KRAS inhibitor-20

Ras Cancer

KRAS inhibitor-20 is a small molecular inhibitor of KRas^G12C, the oncogenic mutant. KRAS inhibitor-20 inhibits KRas^G12C with the IC50 value <10 nM.

HY-P1676A

cyclo(RLsKDK) TFA BK-1361 TFA	MMP	Cancer
cyclo(RLsKDK) (TFA) (BK-1361 (TFA)) is a specific inhibitor of metalloproteinase ADAM8 with an IC₅₀ value of 182 nM. cyclo(RLsKDK) (TFA) has potential applications in inflammatory diseases and cancer.

HY-P1676

cyclo(RLsKDK) BK-1361	MMP	Cancer
cyclo(RLsKDK) (BK-1361) is a specific inhibitor of metalloproteinase ADAM8 with an IC₅₀ value of 182 nM. cyclo(RLsKDK) has potential applications in inflammatory diseases and cancer.

HY-115445

LCS-1	Apoptosis SOD	Cancer
LCS-1 is a superoxide dismutase 1 (SOD1) inhibitor. LCS-1 inhibits SOD1 activity with an IC₅₀ value of 1.07 μM. LCS-1 induces the early- and late-stage apoptosis of multiple myeloma (MM.1S) cells.

HY-136453

CR-1-31-B 3 Publications Verification	Eukaryotic Initiation Factor (eIF) Apoptosis	Cancer
CR-1-31-B is a synthetic rocaglate and a potent eIF4A inhibitor. CR-1-31-B exhibits powerful inhibitory effects over eIF4A by perturbing the interaction between eIF4A and RNA, sequentially impeding initiation during protein synthesis. CR-1-31-B perturbs association of Plasmodium falciparum eIF4A (PfeIF4A) with RNA. CR-1-31-B induces apoptosis of neuroblastoma and gallbladder cancer cells.

HY-10805A

Almorexant hydrochloride 3 Publications Verification ACT 078573 hydrochloride	Orexin Receptor (OX Receptor) Calcium Channel Caspase Apoptosis	Cancer Endocrinology Neurological Disease
Almorexant (ACT 078573) hydrochloride is an orally active, potent and competitive dual orexin receptor antagonist, with K_d values of 1.3 nM (OX1) and 0.17 nM (OX2), respectively. Almorexant hydrochloride reversibly blocks signaling of orexin-A and orexin-B peptides. Almorexant hydrochloride totally blocked the intracellular Ca²⁺ signal pathway. Almorexant hydrochloride stimulates caspase-3 activity in AsPC-1 cells and induces apoptosis.

HY-10805

Almorexant 3 Publications Verification ACT 078573	Orexin Receptor (OX Receptor) Calcium Channel Caspase Apoptosis	Cancer Endocrinology Neurological Disease
Almorexant (ACT 078573) is an orally active, potent and competitive dual orexin receptor antagonist, with K_d values of 1.3 nM (OX1) and 0.17 nM (OX2), respectively. Almorexant reversibly blocks signaling of orexin-A and orexin-B peptides. Almorexant totally blocked the intracellular Ca²⁺ signal pathway. Almorexant stimulates caspase-3 activity in AsPC-1 cells and induces apoptosis.

HY-126255

SBI-797812	NAMPT	Metabolic Disease
SBI-797812 is an orally active nicotinamide phosphoribosyltransferase (NAMPT) activator. SBI-797812 shifts NAMPT to NMN formation, increases NAMPT affinity for ATP, stabilizes phosphorylated NAMPT, promotes consumption of the pyrophosphate by-product, and blunts feedback inhibition by NAD⁺. SBI-797812 increases intracellular nicotinamide mononucleotide (NMN) and elevates liver NAD⁺ in mice.

Cat. No.	Product Name

HY-L103

Anti-Colorectal Cancer Compound Library

1484 compounds

Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer.

Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research. MCE offers a unique collection of 1484 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.

Cat. No.	Product Name	Target	Research Area

HY-P1676A

cyclo(RLsKDK) TFA BK-1361 TFA	MMP	Cancer
cyclo(RLsKDK) (TFA) (BK-1361 (TFA)) is a specific inhibitor of metalloproteinase ADAM8 with an IC₅₀ value of 182 nM. cyclo(RLsKDK) (TFA) has potential applications in inflammatory diseases and cancer.

HY-P5472

Tumour-associated MUC1 epitope	Peptides	Others
Tumour-associated MUC1 epitope is a biological active peptide. (This sequence is the hallmark of MUC1 mucin. MUC1 is a highly glycosylated type I transmembrane glycoprotein with a unique extracellular domain consisting of a variable number of tandem repeats (VNTR) of this 20 amino acid peptide. It is overexpressed on the cell surface of many human adenocarcinomas and hematological malignancies, including multiple myeloma and B-cell lymphoma, making MUC1 broadly applicable target for immunotherapeutic strategies.)

HY-P3203

DSTYSLSSTLTLSK	Peptides	Inflammation/Immunology
DSTYSLSSTLTLSK is a generic human peptide and can be used for infliximab quantitative detection. Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α.

HY-P1676

cyclo(RLsKDK) BK-1361	MMP	Cancer
cyclo(RLsKDK) (BK-1361) is a specific inhibitor of metalloproteinase ADAM8 with an IC₅₀ value of 182 nM. cyclo(RLsKDK) has potential applications in inflammatory diseases and cancer.

Cat. No.	Product Name

HY-K6102

*Human Lung Adenocarcinoma* Organoid Kit**
MCE Human Lung Adenocarcinoma Organoid Kit contains Lung Adenocarcinoma Organoid Basal Medium A, Lung Adenocarcinoma Organoid Supplement B (50x), Lung Adenocarcinoma Organoid Supplement C (250x). This product can be used to efficiently construct human lung adenocarcinoma organoid.

Cat. No.	Product Name	Target	Research Area

HY-P99049

Sotigalimab	Inhibitory Antibodies	Cancer Inflammation/Immunology
Sotigalimab, a CD40 agonistic monoclonal antibody, can be used for the research of metastatic pancreatic adenocarcinoma.

HY-P99350

Gresonitamab AMG 910; Anti-Human CD3xClaudin18 2	CD3	Cancer
Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma.

HY-P99058

Zolbetuximab IMAB362	Inhibitory Antibodies	Cancer
Zolbetuximab (IMAB362) is a monoclonal antibody targeting Claudin-18.2. Zolbetuximab mediates specific killing of Claudin-18.2-positive cells through immune effector mechanisms. Zolbetuximab can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors.

HY-P99278

Adecatumumab MT 201; Anti-Human EPCAM Recombinant Antibody	Inhibitory Antibodies	Cancer
Adecatumumab (Anti-Human EPCAM Recombinant Antibody; MT201) is a full human monoclonal antibody of the IgG1 isotype, targeting human EpCAM. Adecatumumab is expressed in almost all adenocarcinomas, and its activity is not dependent of K-Ras status.